PRRT every 5 weeks
Phase 2Small molecule
PRRT every 5 weeks is one of 10 small molecule programs targeting Tumors. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Fludara
SanofiPhase 2
Tazverik
EEpizyme, Inc.
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Proleukin
IIovance Biotherapeutics, Inc.
Phase 2
Lynparza
AstraZenecaPreclinical
PRRT every 5 weeks
IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2
Lu-177-DOTATATE
NNational Cancer Institute (NCI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tumors1 trial
Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors
Active, not recruiting·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT03454763·618 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PRRT every 5 weeks. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details